- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: anti-hC5aR-32F3A6 GL | IPH-5401 | NN-8210 | NNC-0215-0384
Compound class: Antibody
Comment: Avdoralimab (IPH5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1, and blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. It has immunomodulating activity.
|Targets where the ligand is described in the comment field|
|C5a1 receptor||The C5a1 receptor is currently referred to as C5aR1 in the literature. C5a1 has been an attractive target for pharmacological inhibition to treat a myriad of inflammatory and neurodegenerative diseases. Several C5a1 antagonists have been reported that have progressed to various stages of clinical development [3,5-6], although none are yet approved for use in humans. The non-peptide C5aR1 inhibitor CCX168 (Avacopan®), developed by ChemoCentryx/Amgen, is currently the most clinically advanced C5aR1 inhibitor . The drug was approved by the FDA in October 2021, as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA)) in combination with standard therapy including glucocorticoids . Considering the potential benefits of blocking the C5a-C5a1 axis to limit myeloid infiltration and prevent excessive lung inflammation in Coronavirus disease 2019 (COVID-19) , the two anti-C5a/C5a1 blocking antibodies, avdoralimab (IPH5401) and vilobelimab (IFX-1), were studied in patients with COVID-19 severe pneumonia (NCT04371367 and NCT04333420) .|